Satellos Bioscience Inc.
MSLE
$6.38
$0.304.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 7.31M | -11.46M | 3.99M | 4.44M | 4.54M |
| Gross Profit | -7.31M | 11.46M | -3.99M | -4.44M | -4.54M |
| SG&A Expenses | 2.73M | 2.19M | 1.97M | 1.93M | 1.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.04M | 7.65M | 5.97M | 6.37M | 6.48M |
| Operating Income | -10.04M | -7.65M | -5.97M | -6.37M | -6.48M |
| Income Before Tax | -9.74M | -7.25M | -5.80M | -5.58M | -6.08M |
| Income Tax Expenses | 33.00K | 58.00K | 19.00K | 32.00K | 63.00K |
| Earnings from Continuing Operations | -9.77M | -7.30M | -5.82M | -5.61M | -6.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.77M | -7.30M | -5.82M | -5.61M | -6.14M |
| EBIT | -10.04M | -7.65M | -5.97M | -6.37M | -6.48M |
| EBITDA | -10.04M | -7.65M | -5.96M | -6.37M | -6.48M |
| EPS Basic | -0.53 | -0.47 | -0.42 | -0.39 | -0.44 |
| Normalized Basic EPS | -0.33 | -0.29 | -0.26 | -0.24 | -0.27 |
| EPS Diluted | -0.53 | -0.47 | -0.42 | -0.39 | -0.44 |
| Normalized Diluted EPS | -0.33 | -0.29 | -0.26 | -0.24 | -0.27 |
| Average Basic Shares Outstanding | 18.44M | 15.47M | 13.94M | 14.27M | 13.82M |
| Average Diluted Shares Outstanding | 18.44M | 15.47M | 13.94M | 14.27M | 13.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |